Royalty Pharma's valuation has been showing strong growth lately, even amidst volatile markets. Increasing interest is seen from institutions like
Fjarde AP Fonden Fourth Swedish National Pension Fund,
Asset Management One Co. Ltd. and
TD Asset Management Inc. Analysts hold a consensus rating of 'Buy'. The company also posted
20% portfolio growth, with Q2 receipts at $727M, albeit missing Q2 revenue estimates. Royalty Pharma has a new $2B partnership with
Revolution Medicines, committed $300M to
Zenas’ Obexelimab program and has a proprietary cash printing strategy avoiding biotech's largest risks. Their Q4 2025 dividend has been declared at $0.22 and
Morgan Stanley maintains a buy rating of $55 PT. Investors have also seen notable returns of 41% in the previous year. Recently, a $950M royalties deal with
Amgen for a lung cancer drug has been sealed. However, Q2 earnings and revenues estimates were missed and
Weiss Ratings downgraded the firm to Hold (C+).
Royalty Pharma Stocks News Analytics from Tue, 01 Apr 2025 07:00:00 GMT to Sat, 01 Nov 2025 13:33:35 GMT -
Rating 7
- Innovation 4
- Information 9
- Rumor 5
